Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 540 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... October 18, 2021 EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC October 6, 2020 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 Jimmy Carter Signed This Treaty Demanding An End To Violence Against... May 7, 2021 Load more HOT NEWS Turning the Life Sciences Vision into reality NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC Deputy Spends His Days Off Teaching Life Skills To Young Boys...
